In this interview, Jinling Chen, head of WuXi STA’s drug product business, and Jamie Andrews, site head of WuXi STA’s Couvet facility, explain the company’s strategy and the goals of the European expansion.
WuXi STA has started up a new parenteral formulation line at its drug product site in Wuxi City, China. The company’s second line for parenteral drug product clinical and commercial manufacturing to go on stream this year has an annual capacity of 10 million units.
WuXi STA has opened a sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its campus in Wuxi city, China, in response to rising demand for complex injection dosage forms.
WuXi AppTec and its subsidiary Wuxi STA have announced several investments in manufacturing and research in Asia, with the Changzou campus in China’s Jiangsu Province a focal point.
WuXi Advanced Therapies (Wuxi ATU), US-based CDMO offshoot of WuXi AppTec, is joining up with Singapore’s Bioprocessing Technology Institute (BTI) to advance cell and gene therapy production in the Asia Pacific region.
China’s WuXi AppTec has acquired British gene therapy CDMO Oxgene, making the Oxford-based company a wholly owned subsidiary of the contract testing, development and manufacturing business unit for cell and gene therapies, WuXi Advanced Therapies. With the sale, Oxgene will retain its name.
